NURSING
HOME SITE
- ADULT RETIREMENT COMMUNITIES SITE
Active
Baby Boomers
Promensil
Sponsors America’s First 'Baby Boomer' Pageant
Ms.
Golden America Pageant contestants receive a 30-day supply of Promensil
Naples,
Fla. (PRWEB) October 16, 2005 -- Promensil, a natural supplement that
relieves the symptoms of menopause, has announced it is a product sponsor
for the Ms. Golden America Pageant, which will be held on October 29,
2005, at the Harborside Event Center in Fort Myers, Fla.
Ms.
Golden America is a pageant focusing on the beauty and accomplishments
of women age 50 and older. While 750 women from around the country applied
to compete in the inaugural pageant, only 15 will vie for the title
of Ms. Golden America. The five categories of competition are: tennis
wear, consumer appeal, written essay, traditional evening gowns and
on-stage questions.
Ms.
Golden America will be broadcast as a one-hour special on the SkyAngel
cable network on December 17, 2005.
Promensil
is a natural supplement that has been clinically proven to relieve the
symptoms of menopause, including hot flashes and night sweats, as well
as maintain bone and cardiovascular health; Promensil Post Menopause
is designed to help post midlife women maintain bone and cholesterol
health after menopause. Both are products of Novogen, Ltd, world leader
in isoflavone research, and can be purchased over the counter at pharmacies,
health food/nutrition/vitamin and retail stores everywhere. For more
information, visit www.promensil.com.
Information
about the Ms. Golden America Pageant may be obtained by calling Kathleen
LeSage at 1-800 545-9407 or on their website, www.msgoldenamerica.com.
Novogen,
Ltd., is the world leader in research and development of isoflavones
for human health. Isoflavones derived from the red clover plant, marketed
under the brand name Promensil, have been clinically proven safe and
effective in treating the symptoms of menopause and improving cardiovascular
and bone health.
Phenoxodiol,
the Company's leading anti-cancer compound, has received Fast Track
designation for recurrent ovarian cancer as well as for hormone refractory
prostate cancer from the Food and Drug Administration in the U.S. The
rights to commercialize this drug are licensed to the Company's majority
owned subsidiary, Marshall Edwards, Inc., (Nasdaq: MSHL - News; LSE-AIM:
MSHL). More information can be found at http://www.novogen.com
and http://www.marshalledwardsinc.com.